Vpr Promotes Macrophage-Dependent HIV-1 Infection of CD4+ T Lymphocytes

PLoS Pathogens

Volumn 11, Issue 7, 2015, Pages

  Collins, David R ^a   Lubow, Jay ^a   Lukic, Zana ^b   Mashiba, Michael ^a   Collins, Kathleen L ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; VPR PROTEIN; ALPHA INTERFERON;

ARTICLE; CD4+ T LYMPHOCYTE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOBLOTTING; MACROPHAGE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; VIRUS EXPRESSION; VIRUS REPLICATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; VIRION; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; PRIMATES;

CD4-POSITIVE T-LYMPHOCYTES; HIV-1; HUMANS; INTERFERON-ALPHA; MACROPHAGES; VIRION; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84938790385     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005054     Document Type: Article

References (50)

1. Rockstroh JK, Mudar M, Lichterfeld M, Nischalke HD, Klausen G, et al. (2002) Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients. AIDS 16: 2083–2085. 12370510
2. Hoch J, Lang SM, Weeger M, Stahl-Hennig C, Coulibaly C, et al. (1995) vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys. J Virol 69: 4807–4813. 7609047
3. Lang SM, Weeger M, Stahl-Hennig C, Coulibaly C, Hunsmann G, et al. (1993) Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J Virol 67: 902–912. 8380472
4. Rucker E, Grivel JC, Munch J, Kirchhoff F, Margolis L, (2004) Vpr and Vpu are important for efficient human immunodeficiency virus type 1 replication and CD4+ T-cell depletion in human lymphoid tissue ex vivo. J Virol 78: 12689–12693. 15507658
5. Balliet JW, Kolson DL, Eiger G, Kim FM, McGann KA, et al. (1994) Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. Virology 200: 623–631. 8178448
6. Planelles V, Bachelerie F, Jowett JB, Haislip A, Xie Y, et al. (1995) Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr. J Virol 69: 5883–5889. 7637036
7. Rogel ME, Wu LI, Emerman M, (1995) The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol 69: 882–888. 7815556
8. Laguette N, Bregnard C, Hue P, Basbous J, Yatim A, et al. (2014) Premature activation of the SLX4 complex by Vpr promotes G2/M arrest and escape from innate immune sensing. Cell 156: 134–145. doi: 10.1016/j.cell.2013.12.011 24412650
9. Belzile JP, Richard J, Rougeau N, Xiao Y, Cohen EA, (2010) HIV-1 Vpr induces the K48-linked polyubiquitination and proteasomal degradation of target cellular proteins to activate ATR and promote G2 arrest. J Virol 84: 3320–3330. doi: 10.1128/JVI.02590-09 20089662
10. Le Rouzic E, Belaidouni N, Estrabaud E, Morel M, Rain JC, et al. (2007) HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle 6: 182–188. 17314515
11. Mashiba M, Collins DR, Terry VH, Collins KL, (2014) Vpr Overcomes Macrophage-Specific Restriction of HIV-1 Env Expression and Virion Production. Cell Host Microbe.
12. Guenzel CA, Herate C, Benichou S, (2014) HIV-1 Vpr-a still "enigmatic multitasker". Front Microbiol 5: 127. doi: 10.3389/fmicb.2014.00127 24744753
13. Kirchhoff F, (2010) Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 8: 55–67. doi: 10.1016/j.chom.2010.06.004 20638642
14. Schiffner T, Sattentau QJ, Duncan CJ, (2013) Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies. Vaccine 31: 5789–5797. doi: 10.1016/j.vaccine.2013.10.020 24140477
15. Durham ND, Yewdall AW, Chen P, Lee R, Zony C, et al. (2012) Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tail. J Virol 86: 7484–7495. doi: 10.1128/JVI.00230-12 22553332
16. Duncan CJ, Williams JP, Schiffner T, Gartner K, Ochsenbauer C, et al. (2014) High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse. J Virol 88: 2025–2034. doi: 10.1128/JVI.03245-13 24307588
17. Massanella M, Puigdomenech I, Cabrera C, Fernandez-Figueras MT, Aucher A, et al. (2009) Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells. AIDS 23: 183–188. doi: 10.1097/QAD.0b013e32831ef1a3 19098487
18. McDonald D, (2010) Dendritic Cells and HIV-1 Trans-Infection. Viruses 2: 1704–1717. doi: 10.3390/v2081704 21994702
19. Peressin M, Proust A, Schmidt S, Su B, Lambotin M, et al. (2014) Efficient transfer of HIV-1 in trans and in cis from Langerhans dendritic cells and macrophages to autologous T lymphocytes. AIDS 28: 667–677. doi: 10.1097/QAD.0000000000000193 24451159
20. O'Doherty U, Swiggard WJ, Malim MH, (2000) Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 74: 10074–10080. 11024136
21. Goh WC, Rogel ME, Kinsey CM, Michael SF, Fultz PN, et al. (1998) HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med 4: 65–71. 9427608
22. Stivahtis GL, Soares MA, Vodicka MA, Hahn BH, Emerman M, (1997) Conservation and host specificity of Vpr-mediated cell cycle arrest suggest a fundamental role in primate lentivirus evolution and biology. J Virol 71: 4331–4338. 9151821
23. Mashiba M, Collins KL, (2013) Molecular mechanisms of HIV immune evasion of the innate immune response in myeloid cells. Viruses 5: 1–14.
24. Connor RI, Chen BK, Choe S, Landau NR, (1995) Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206: 935–944. 7531918
25. Ahn J, Vu T, Novince Z, Guerrero-Santoro J, Rapic-Otrin V, et al. (2010) HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for proteasome-dependent degradation. J Biol Chem 285: 37333–37341. doi: 10.1074/jbc.M110.133181 20870715
26. Casey Klockow L, Sharifi HJ, Wen X, Flagg M, Furuya AK, et al. (2013) The HIV-1 protein Vpr targets the endoribonuclease Dicer for proteasomal degradation to boost macrophage infection. Virology 444: 191–202. doi: 10.1016/j.virol.2013.06.010 23849790
27. Collins DR, Collins KL, (2014) HIV-1 accessory proteins adapt cellular adaptors to facilitate immune evasion. PLoS Pathog 10: e1003851. doi: 10.1371/journal.ppat.1003851 24465204
28. DeHart JL, Zimmerman ES, Ardon O, Monteiro-Filho CM, Arganaraz ER, et al. (2007) HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol J 4: 57. 17559673
29. Pertel T, Reinhard C, Luban J, (2011) Vpx rescues HIV-1 transduction of dendritic cells from the antiviral state established by type 1 interferon. Retrovirology 8: 49. doi: 10.1186/1742-4690-8-49 21696578
30. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ, (2004) HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med 199: 283–293. 14734528
31. Dale BM, Alvarez RA, Chen BK, (2013) Mechanisms of enhanced HIV spread through T-cell virological synapses. Immunol Rev 251: 113–124. doi: 10.1111/imr.12022 23278744
32. Groot F, Welsch S, Sattentau QJ, (2008) Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood 111: 4660–4663. doi: 10.1182/blood-2007-12-130070 18296630
33. Giese S, Marsh M, (2014) Tetherin can restrict cell-free and cell-cell transmission of HIV from primary macrophages to T cells. PLoS Pathog 10: e1004189. doi: 10.1371/journal.ppat.1004189 24991932
34. Del Portillo A, Tripodi J, Najfeld V, Wodarz D, Levy DN, et al. (2011) Multiploid inheritance of HIV-1 during cell-to-cell infection. J Virol 85: 7169–7176. doi: 10.1128/JVI.00231-11 21543479
35. Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, et al. (2013) Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis 207: 213–222. doi: 10.1093/infdis/jis663 23105144
36. Sun H, Buzon MJ, Shaw A, Berg RK, Yu XG, et al. (2014) Hepatitis C therapy with interferon-alpha and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients. J Infect Dis 209: 1315–1320. doi: 10.1093/infdis/jit628 24277743
37. Hatch WC, Tanaka KE, Calvelli T, Rashbaum WK, Kress Y, et al. (1992) Persistent productive HIV-1 infection of a CD4- human fetal thymocyte line. J Immunol 148: 3055–3061. 1374448
38. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, et al. (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75: 10892–10905. 11602729
39. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, et al. (1994) Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 10: 359–369. 7520721
40. Burton DR, Barbas CF, 3rdPersson MA, Koenig S, Chanock RM, et al. (1991) A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci U S A 88: 10134–10137. 1719545
41. McCallus DE, Ugen KE, Sato AI, Williams WV, Weiner DB, (1992) Construction of a recombinant bacterial human CD4 expression system producing a bioactive CD4 molecule. Viral Immunol 5: 163–172. 1319711
42. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, et al. (1986) Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59: 284–291. 3016298
43. Collman R, Balliet JW, Gregory SA, Friedman H, Kolson DL, et al. (1992) An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol 66: 7517–7521. 1433527
44. Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, et al. (1991) Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and-defective viral genomes. J Virol 65: 3973–3985. 1830110
45. Pertel T, Hausmann S, Morger D, Zuger S, Guerra J, et al. (2011) TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472: 361–365. doi: 10.1038/nature09976 21512573
46. Sullivan N, Sun Y, Li J, Hofmann W, Sodroski J, (1995) Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol 69: 4413–4422. 7769703
47. Zimmerman ES, Sherman MP, Blackett JL, Neidleman JA, Kreis C, et al. (2006) Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J Virol 80: 10407–10418. 16956949
48. McNamara LA, Ganesh JA, Collins KL, (2012) Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-kappaB activation. J Virol 86: 9337–9350. doi: 10.1128/JVI.00895-12 22718820
49. Norman JM, Mashiba M, McNamara LA, Onafuwa-Nuga A, Chiari-Fort E, et al. (2011) The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. Nat Immunol 12: 975–983. doi: 10.1038/ni.2087 21874023
50. Carter CC, Onafuwa-Nuga A, McNamara LA, Riddell Jt, Bixby D, et al. (2010) HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 16: 446–451. doi: 10.1038/nm.2109 20208541